IQ EQ FUND MANAGEMENT IRELAND Ltd Has $7.53 Million Stock Position in Stryker Corporation $SYK

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Stryker Corporation (NYSE:SYK) by 7.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,034 shares of the medical technology company’s stock after buying an additional 1,320 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Stryker were worth $7,530,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of SYK. Brighton Jones LLC increased its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Stryker by 7.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 44,258 shares of the medical technology company’s stock worth $16,162,000 after buying an additional 2,892 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Stryker by 24.1% during the first quarter. Golden State Wealth Management LLC now owns 247 shares of the medical technology company’s stock worth $92,000 after buying an additional 48 shares in the last quarter. Avidian Wealth Enterprises LLC lifted its stake in shares of Stryker by 1.6% in the 1st quarter. Avidian Wealth Enterprises LLC now owns 2,722 shares of the medical technology company’s stock valued at $1,013,000 after acquiring an additional 42 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Stryker by 1.2% during the 1st quarter. Amalgamated Bank now owns 71,932 shares of the medical technology company’s stock valued at $26,777,000 after acquiring an additional 824 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on SYK shares. Evercore ISI lowered their target price on Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. UBS Group set a $408.00 price objective on Stryker in a research note on Monday, October 13th. Needham & Company LLC lifted their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday, September 18th. Finally, Barclays raised their price target on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $432.24.

Insider Activity

In related news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Up 0.5%

Shares of NYSE SYK opened at $383.56 on Tuesday. The company’s 50 day moving average price is $379.87 and its 200-day moving average price is $380.29. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a market capitalization of $146.64 billion, a P/E ratio of 50.80, a price-to-earnings-growth ratio of 2.75 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.